Key result
Levosimendan improves hemodynamics and symptoms in decompensated heart failure by increasing calcium sensitivity, though its long-term impact on mortality requires further large-scale studies.
Why the study?
Does levosimendan improve hemodynamics and symptoms in patients with decompensated heart failure?
Does levosimendan improve hemodynamics and symptoms in patients with decompensated heart failure?
Levosimendan is a promising calcium sensitizer that improves hemodynamics and symptoms in decompensated heart failure, though its long-term mortality impact requires further study.
Answers are grounded in this paper and cite their sources.
May support short-term levosimendan use in decompensated HF; leaves mortality effects open for larger trials.
Levosimendan increases the sensitivity of the cardiac fibrils to calcium, favorably affects hemodynamics in patients with heart failure. It is a positive inotrope and a peripheral vasodilator. The elimination half-life of the compound is about 1 hour. The drug decreases pulmonary capillary wedge pressure, increases cardiac output with the improvement in left ventricular ejection fraction leading to symptomatic improvement which includes decreased dyspnea and fatigue. Levosimendan can be used safely with diuretics, nitrates, beta-blockers, digoxin, and angiotensin-converting enzyme inhibitors. The most common adverse effects of levosimendan are headache and hypotension. Prolongation of the QTc interval does not appear to increase the incidence of arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes. Levosimendan is a novel agent in the treatment of decompensated heart failure, representing a newer class of medications aimed at increasing calcium sensitivity. Its properties holds promise for the treatment of heart failure but further large-scale studies will be needed to determine its precise efficacy, safety, as well as the compound's long-term impact on mortality.
No takes yet. Share an insight, caveat, or question.
Kota et al. (2008) conducted a review in Decompensated heart failure. Levosimendan was evaluated. Levosimendan improves hemodynamics and symptoms in decompensated heart failure by increasing calcium sensitivity, though its long-term impact on mortality requires further large-scale studies.
Synapse has enriched 10 related papers. Consider them for comparative context: